Next, we tested whether combined systemic inhibition of HIF-1α with 2ME2 and TGF-β with a TβRI kinase inhibitor SD-208 [14], [31] provided additional therapeutic benefit in a therapeutic model of breast cancer bone metastasis. Here, TGFB1 is linked to breast cancer.